Influenza

Efficacy results for FluBlOk recombinant influenza vaccine reported

Published in Hepatitis Weekly, July 11th, 2005

Protein Sciences Corporation announced preliminary results from its first field efficacy study of FluBlOk, a patented influenza vaccine that is produced in insect cells without live influenza viruses, eggs or preservatives such as thimerosal.

The study enrolled 460 healthy subjects aged 18 to 49 into three equal arms at three sites in the United States during the 2004/05 influenza season. Subjects received one of the two different doses of FluBlOk (the concentration of the H1 and B antigens was different and the H3 antigen the same in the two FluBlOk formulations) or placebo. The study subjects were followed for influenza-like illnesses (ILI) and those who developed ILI...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-07-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry